AI assistant
Telix Pharmaceuticals Ltd — Board/Management Information 2018
Jun 18, 2018
31324_rns_2018-06-18_057aa108-e9c1-4b3b-aca1-0fe422f615a5.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [143 x 79] intentionally omitted <==
Telix Pharmaceuticals appoints Jann Skinner to Board of Directors
Melbourne, Australia – 19 June 2018. Telix Pharmaceuticals Limited (ASX.TLX), a clinical-stage oncology company developing a pipeline of products based on “molecularly-targeted radiation”, is pleased to announce the appointment of Ms. Jann E. Skinner to the Board as a Non-Executive Director.
Ms. Skinner, B Com, FCA, FAICD has extensive experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004.
- Jann is an independent non executive director of QBE Insurance Group Limited, where she also serves as Deputy Chair of the Risk and Capital Committee and the Audit Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. Jann is a Fellow of both Chartered Accountants Australia & New Zealand, and the Australian Institute of Company Directors.
Chair of the Board, Kevin McCann said, “We are very pleased to have Jann join the Board of Telix Pharmaceuticals. Jann brings considerable experience in audit and accounting and governance and risk management. In addition, her depth of knowledge and expertise in listed boards will be invaluable to Telix.”
Ms Skinner will serve as Chair of the Audit and Risk Management Committee.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
Corporate Contact Investor and Media Relations (Australia)
Dr Christian Behrenbruch Telix Pharmaceuticals Limited Managing Director & CEO Email: [email protected]
Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: [email protected]
Page 1